Mesutoclax clinical trials
Also written ICP-248.
How each study uses mesutoclax is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the mesutoclax studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ICP-248
- 7
Studies by the year they started
7 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Beijing InnoCare Pharma Tech Co., Ltd. (6) · InnoCare Pharma Inc. (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test mesutoclax.
- Jun 2027ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid MalignanciesPhase 1 · Beijing InnoCare Pharma Tech Co., Ltd.
- Jun 2027Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell MalignanciesPhase 1 · InnoCare Pharma Inc.
Studies
Open first, then newest update. How each study uses mesutoclax is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone LymphomaNot yet recruitingPhase 3Beijing InnoCare Pharma Tech Co., Ltd.NCT07896590Written as ICP-248
- A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).Not yet recruitingPhase 3Beijing InnoCare Pharma Tech Co., Ltd.NCT07784101Written as ICP-248
- ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid MalignanciesRecruitingPhase 1Beijing InnoCare Pharma Tech Co., Ltd.NCT06656494Written as ICP-248
- A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)RecruitingPhase 2Beijing InnoCare Pharma Tech Co., Ltd.NCT07082686Written as ICP-248
- ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)RecruitingPhase 2/3Beijing InnoCare Pharma Tech Co., Ltd.NCT06378138Written as ICP-248
- The Study of ICP-248 in Patients With Mature B-cell MalignanciesRecruitingPhase 1Beijing InnoCare Pharma Tech Co., Ltd.NCT05728658Written as ICP-248
- Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell MalignanciesRecruitingPhase 1InnoCare Pharma Inc.NCT06351527Written as ICP-248
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
- Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone LymphomaOct 27, 2026NCT07896590
Codes
What other systems call mesutoclax · ClinicalTrials.gg INT015136
- UNII (FDA) 5WGC3F4X8KMESUTOCLAXOne source FDA
- NCI Thesaurus C215084MesutoclaxOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5WGC3F4X8K | MESUTOCLAX | One source FDA |
| NCI Thesaurus | C215084 | Mesutoclax | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.